BioAtla IPO Presentation Deck

BA3011 AXL-ADC Phase 2 Clinical Program Potentially Registration-Enabling Phase 2 Trials (RP2D: 1.8mg/kg Q2W) STS Bone sarcoma STS & Bone sarcoma Phase 2 - Sarcoma-mono and/or combo with PD-1; BA3011 dose: 1.8mg/kg Q2W; AXL TmPS 270; 3rd line n=165-240 BA3011 Monotherapy (n=40) BA3011 Monotherapy (n=30) Combo with PD-1 (n=20) CD20 positive and negative Phase 2 NSCLC mono & combo with PD-1 in PD-1 exposed patients (n=20) Timeline Sarcoma: • 3rd line patients (chemotherapy failure) Interim analysis Selected ST5 & bone subtypes (n-150) mono &/or combo w PD-1 AXL positive Primary endpoint: ORR Matching population synthetic arm Phase 2 Population Proof Of Concept read-out (POC) Secondary endpoints: "PFS; OS Data read-out Ovarian Investigator-Initiated Trial (IIT) not shown NSCLC: • Prior disease progression on PD- 1/L1 inhibitor Note: "TmPS= Tumor membrane Percent Score-Scores range from 0 to 100; "PFS progression-free survival, OS = overall survival bicatla 15

View entire presentation